DeutschNewstral
Article
bizjournals.com on 2021-01-12 21:20
Baltimore biotech Delfi Diagnostics raises $100 million funding round
Related news
- Baltimore biotech developing diabetes treatments raises $20.5Mbizjournals.com
- Baltimore biotech WindMIL Therapeutics raises $32.5 millionbizjournals.com
- Best in Tech Awards 2021: Delfi Diagnosticsbizjournals.com
- Baltimore biotech targeting rare diseases raises $4 millionbizjournals.com
- Baltimore biotech raises $1.6M to put toward wound healing solutionbizjournals.com
- Former PGDx, Delfi Diagnostics CFO joins new cancer-detection startupbizjournals.com
- Baltimore fintech Facet Wealth raises $100M in Series C fundingbizjournals.com
- Baltimore biotech raises $4M to fuel trials for Covid vaccine, rare disease drugbizjournals.com
- Delfi Diagnostics' tech shows early success in detecting 90% of lung cancer casesbizjournals.com
- Baltimore's Personal Genome Diagnostics raises $21.4 millionbizjournals.com
- Baltimore fintech Facet Wealth raises $25 million in Series B fundingbizjournals.com
- Cancer diagnostics company raises $2.5M in fundingbizjournals.com
- Baltimore biotech firm raising $111.5 millionbizjournals.com
- Former Sucampo CEO lands at Baltimore biotechbizjournals.com
- St. Louis biotech startup relocates to Baltimorebizjournals.com
- Personal Genome Diagnostics raises $4.3M in ongoing Series Abizjournals.com
Baltimore biotech firm launches kit for rapid DNA extractionthedailyrecord.com
Biotech company to manufacture Ebola treatment in Baltimorewkrg.com- California public company Pacific Biosciences acquires Baltimore biotechbizjournals.com
- Baltimore biotech bringing new cancer diagnosis test to marketbizjournals.com